  | MATERNE, C., Masson, V., Pirotte, B., Rigo, V., Uurlings, F., & Schmitz, V. (May 2025). Les nouvelles recommandations de prise en charge mère-enfant en cas de VIH. Revue Médicale de Liège, 80 (5-6), 428 - 435.  Editorial Reviewed verified by ORBi |
  | MAWET, M., Brichant, G., Thielen, V., Masson, V., & Chantraine, F. (April 2025). Kwashiorkor during pregnancy: A rare complication of bariatric surgery with fetal health consequences. European Journal of Obstetrics and Gynecology and Reproductive Biology, 307, 277 - 278. doi:10.1016/j.ejogrb.2025.02.003 Peer Reviewed verified by ORBi |
 | Nulens, K., Papy, E., Tartaglia, K., Dehaene, I., Logghe, H., Van Keirsbilck, J., Chantraine, F., Masson, V., Simoens, E., Gysemans, W., Bruckers, L., Lebeer, S., Allonsius, C. N., Oerlemans, E., Steensels, D., Reynders, M., Timmerman, D., Devlieger, R., & Van Holsbeke, C. (17 September 2024). Synbiotics in patients at risk for spontaneous preterm birth: protocol for a multi-centre, double-blind, randomised placebo-controlled trial (PRIORI). Trials, 25 (1), 615. doi:10.1186/s13063-024-08444-8 Peer Reviewed verified by ORBi |
 | ALLARD, M., GROSCH, S., Jouret, F., Masson, V., Surinder, T., & Masset, C. (June 2024). Prévention de la prééclampsie et de ses complications. Revue Médicale de Liège, 79 (5-6), 448 - 454. Editorial Reviewed verified by ORBi |
 | Servais, V., HABRAN, C., Masson, V., Nisolle, M., & Henry, L. (June 2024). Prévention de l’infertilité : reconnaître et cibler les nombreux facteurs de risque. Revue Médicale de Liège, 79 (5-6), 442 - 447. Editorial Reviewed verified by ORBi |
 | HOYOUX, M., Snoeck, M., Sondag, C., Ketelslegers, O., Minon, J. M., Azerad, M.-A., MASSON, V., & DRESSE, M.-F. (November 2019). Prise en charge multidisciplinaire du patient drepanocytaire pediatrique en 2019. Revue Médicale de Liège, 74 (11), 586-592. Peer reviewed |
 | Swenen, L., BRICHANT, G., Kaluanga, A., MASSON, V., & NISOLLE, M. (January 2017). Les mutilations génitales féminines: la situation à Liège. Revue Médicale de Liège, 72 (1), 25-31. Peer reviewed |
 | Lefebvre, C., MASSON, V., Kalenga, M., & RIGO, V. (12 March 2015). Implementation of placental transfusion protocol. Tijdschrift van de Belgische Kinderarts, 17 (1), 72. Peer reviewed |
 | Lefebvre, C., MASSON, V., Kalenga, M., & RIGO, V. (March 2015). Benefits of placental transfusion in very preterm infants. Tijdschrift van de Belgische Kinderarts, 17 (1), 84. Peer reviewed |
 | Emonts, P., MASSON, V., CHANTRAINE, F., Kridelka, F., & Nisolle, M. (2013). Assuétudes et grossesse: comment détruire un projet de naissance. Revue Médicale de Liège, 68 (5-6), 239-244. Peer reviewed |
 | Masson, V., Petit, P., & Foidart, J.-M. (2010). Défaut d'observance et inertie therapeutique en obstétrique. Revue Médicale de Liège, 65 (5-6), 395-8. Peer reviewed |
 | Absil, G., Vandoorne, C., Masson, V., Prato, E., & Foidart, J.-M. (October 2009). L'entretien prénatal : de la rencontre des parents à l'organisation de la communication entre les professionnels [Poster presentation]. 39èmes journées nationales de la Société Française de Médecine Périnatale, Angers, France. |
 | Masson, V., de la Ballina, L. R., Munaut, C., Wielockx, B., Jost, M., Maillard, C., Blacher, S., Bajou, K., Itoh, T., Itohara, S., Werb, Z., Libert, C., Foidart, J.-M., & Noël, A. (February 2005). Contribution of Host MMP-2 and MMP-9 to Promote Tumor Vascularization and Invasion of Malignant Keratinocytes. FASEB Journal, 19 (2), 234-6. doi:10.1096/fj.04-2140fje Peer Reviewed verified by ORBi |
 | Rakic, J.-M., Maillard, C., Jost, M., Bajou, K., Masson, V., Devy, L., Lambert, V., Foidart, J.-M., & Noël, A. (March 2003). Role of plasminogen activator-plasmin system in tumor angiogenesis. Cellular and Molecular Life Sciences, 60 (3), 463-473. doi:10.1007/s000180300039 Peer Reviewed verified by ORBi |
 | Masson, V., Devy, L., Grignet, C., Berndt, S., Bajou, K., Blacher, S., Roland, G., Chang, Y., Fong, T., Carmeliet, P., Foidart, J.-M., & Noël, A. (28 October 2002). Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. Biological Procedures Online, 4, 24-31. doi:10.1251/bpo30 Peer Reviewed verified by ORBi |
 | Devy, L., Blacher, S., Grignet, C., Bajou, K., Masson, V., Gerard, R. D., Gils, A., Carmeliet, G., Carmeliet, P., Declerck, P. J., Noël, A., & Foidart, J.-M. (February 2002). The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB Journal, 16 (2), 147-54. doi:10.1096/fj.01-0552com Peer Reviewed verified by ORBi |
Noël, A., Albert, V., Bajou, K., Bisson, C., Devy, L., Frankenne, F., Maquoi, E., Masson, V., Sounni, N. E., & Foidart, J.-M. (April 2001). New Functions of Stromal Proteases and Their Inhibitors in Tumor Progression. Surgical Oncology Clinics of North America, 10 (2), 417-32. doi:10.1016/s1055-3207(18)30073-5 Peer Reviewed verified by ORBi |
 | Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brunner, N., Dano, K., Fusenig, N. E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J.-M., & Noël, A. (10 February 2001). The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin. Implications for Antiangiogenic Strategies. Journal of Cell Biology, 152 (4), 777-84. doi:10.1083/jcb.152.4.777 Peer Reviewed verified by ORBi |
Bajou, K., Devy, L., Masson, V., Albert, V., Frankenne, F., Noël, A., & Foidart, J.-M. (2001). Role de l'inhibiteur des activateurs de plasminogene de type 1 dans l'angiogenese tumorale. Thérapie, 56 (5, Sep-Oct), 465-72. Peer Reviewed verified by ORBi |
 | Van den Brule, F., DESREUX, J., BELIARD, A., MASSON, V., Noël, A., Kebers, F., Thomas, J., GASPARD, U., & Foidart, J.-M. (2001). Influence du régime d’administration continu ou discontinu d’acétate de nomégestrol sur l’apoptose des cellules mammaires. Reproduction Humaine et Hormones, 15, 243-248. Peer reviewed |
Frankenne, F., Noël, A., Bajou, K., Sounni, N. E., Goffin, F., Masson, V., Munaut, C., Remacle, A., & Foidart, J.-M. (September 1999). Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy. Expert Opinion on Therapeutic Targets, 3 (3), 469-481 (13. doi:10.1517/14728222.3.3.469 Peer Reviewed verified by ORBi |
 | Noël, A., Bajou, K., Masson, V., Frankenne, F., Rakic, J.-M., Lambert, V., Carmeliet, P., & Foidart, J.-M. (1999). Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1. Fibrinolysis and Proteolysis, 13 (6), 220-225. doi:10.1054/fipr.2000.0043 Peer reviewed |
DESREUX, J., GOFFIN, F., BELIARD, A., MASSON, V., Kebers, F., Thomas, J., & Foidart, J.-M. (1999). L’apoptose mammaire dans le sein normal et en pathologie. Références en Gynécologie Obstétrique, 6, 33-40. Peer reviewed |
 | Bajou, K., Noël, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., & Foidart, J.-M. (August 1998). Absence of Host Plasminogen Activator Inhibitor 1 Prevents Cancer Invasion and Vascularization. Nature Medicine, 4 (8), 923-8. doi:10.1038/nm0898-923 Peer Reviewed verified by ORBi |
